Jade Biosciences (JBIO) Share-based Compensation (2020 - 2026)
Jade Biosciences (JBIO) posted Share-based Compensation of $7.4 million for Q1 2026, down 21.19% on a QoQ basis from $9.4 million in Q4 2025, and up 205.61% year-over-year from $2.4 million in Q1 2025.
Jade Biosciences (JBIO) Share-based Compensation (2020 - 2026) Analysis & Trends
Jade Biosciences' Share-based Compensation history runs 7 years deep, the most recent figure standing at $7.4 million for Q1 2026.
- Quarterly Share-based Compensation rose 205.61% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.0 million (up 230.09% YoY) and the FY2025 annual result came in at $20.0 million, up 76.9% from the prior year.
- Share-based Compensation was $7.4 million for Q1 2026 at Jade Biosciences, down from $9.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $9.4 million in Q4 2025 and bottomed at $27000.0 in Q3 2024.
- A 5-year average of $3.4 million and a median of $3.2 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation sank 99.17% — and 2025, when it jumped 15807.41%.
- Jade Biosciences' Share-based Compensation stood at $4.7 million in 2022, then sank by 30.99% to $3.3 million in 2023, then slumped by 61.37% to $1.3 million in 2024, then soared by 648.09% to $9.4 million in 2025, then fell by 21.19% to $7.4 million in 2026.
- Business Quant data shows JBIO's Share-based Compensation at $7.4 million in Q1 2026, $9.4 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Jade Biosciences | 16.25 Mn | 16.25 Mn | - | 7.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.41 Mn |
| Mar 31, 2026 | 7.41 Mn |
| Dec 31, 2025 | 9.40 Mn |
| Dec 31, 2025 | 9.40 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 3.87 Mn |
| Jun 30, 2024 | 3.87 Mn |
| Mar 31, 2024 | 4.20 Mn |
| Mar 31, 2024 | 4.20 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Dec 31, 2023 | 3.25 Mn |